查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1970854

妊娠相關高血壓診斷市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、最終用戶、地區和競爭對手分類，2021-2031年

Preeclampsia Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球子癇前症診斷市場預計將從 2025 年的 8.4903 億美元成長到 2031 年的 11.0947 億美元，複合年成長率為 4.56%。

此領域涵蓋用於識別妊娠高血壓疾病的醫療設備和檢測套組（例如血壓監測儀、尿蛋白尿液檢查試劑盒和胎盤生長因子生物標記）。推動該領域成長的主要因素是全球孕產婦風險因素（例如肥胖、慢性高血壓和高齡生產）發生率的上升，這些風險因素需要嚴格的產前監測。此外，將早期風險評估通訊協定納入常規產前檢查以及政府主導的降低孕產婦死亡率的舉措，也為市場擴張提供了基礎性支撐，而與具體的技術趨勢無關。

市場概覽
預測期 2027-2031
市場規模：2025年 8.4903億美元
市場規模：2031年 11.0947億美元
複合年成長率：2026-2031年 4.56%
成長最快的細分市場 消耗品
最大的市場 北美洲

然而，特定生物標記檢測的成本效益和可近性方面存在著許多阻礙市場成長的重大障礙，尤其是在疾病負擔沉重的資源匱乏地區。這種差距限制了有效篩檢工具的廣泛應用，而這些工具對於預防嚴重臨床後果至關重要。妊娠毒血症基金會2024年的資料顯示，妊娠毒血症及相關高血壓疾病每年在全球造成約7.6萬名孕產婦和50萬名嬰兒死亡，凸顯了這些診斷缺口的嚴重性。

市場促進因素

基於生物標記的診斷檢測技術的進步是推動市場發展的關鍵因素，它將治療標準從被動反應轉向預測性風險分層。業界正迅速採用評估血管新生因子（例如 sFlt-1/PlGF 比值）的檢測方法，這些方法與傳統的血壓測量和蛋白尿尿液檢查相比，具有更高的預測準確性。例如，LabCorp 於 2024 年 5 月發布的「早期妊娠毒血症篩檢測試」表明，該新方法在檢測早期風險方面靈敏度高達 90%，顯著優於傳統的評估方法。這種診斷準確性將促使其在臨床工作流程中得到更廣泛的應用，並加快介入速度，從而直接提升診斷設備製造商的收入。

同時，由於子癇前症發病率的上升，市場也不斷擴張。這一趨勢與高齡生產以及育齡婦女中肥胖、糖尿病等慢性疾病的日益普遍密切相關。根據美國早產兒基金會（March of Dimes）於2024年11月發布的《2024年報告卡》，2022年至2023年間，美國子癲前症的發病率成長超過10%，因此需要對不斷擴大的高危險群進行頻繁的診斷監測。 2024年5月，《Femtech Insider》雜誌發表了一篇題為《Labcorp推出妊娠毒血症風險篩檢新測試》的報導，強調了這項疾病的廣泛影響。報導指出，目前美國每25例妊娠中就有1例受到妊娠毒血症的影響，凸顯了精準診斷解決方案的緊迫性。

市場挑戰

在資源匱乏的環境中，專業生物標記檢測的高昂成本和有限的普及程度是限制全球妊娠毒血症診斷市場發展的主要阻礙因素。儘管發展中地區對嚴格的產前監測有著極高的臨床需求，但資金和基礎設施的限制往往阻礙了先進診斷設備和檢查室分析技術的應用。這種差距使得市場參與企業難以在高需求地區企業發展，從而有效地將潛在市場規模限制在主要高所得國家。因此，疾病盛行率與經濟購買力之間的差距減緩了這些關鍵工具在全球的普及。

這些經濟壁壘直接影響產業收入，因為全球仍有相當一部分患者無法獲得醫療保健服務。進入這些市場的困難導致潛在銷售量成長大幅下降，因為企業無法在臨床負擔最重的地區擴大規模。世界衛生組織（世衛組織）2024年報告顯示，約92%的孕產婦死亡發生在低收入和中低收入國家。這項數據凸顯了嚴重的市場失衡，顯示對診斷工具需求最高的地區最難取得這些工具，阻礙了整個產業的擴張。

市場趨勢

人工智慧驅動的預測分析的整合正在從根本上改變市場格局，它能夠處理複雜的生理數據，從而實現非侵入性、高精度的篩檢方法。這一趨勢超越了傳統的蛋白質檢測，利用機器學習演算法分析視網膜血管變化等新型輸入數據，實現疾病的早期檢測。這些數位化工具增強了篩檢的擴充性，提供了超越傳統風險因素評估的預測能力，並加速了軟體產品作為醫療設備的開發。正如 Medscape 2024 年 3 月號報導的《人工智慧識別妊娠毒血症的視網膜生物標記》中所述，新近評估的人工智慧框架「DVT-Net」在妊娠早期和中期預測子癲前症的準確率達到了 0.813，顯著提高了症狀出現前識別高風險患者的能力。

同時，遠端和居家監測解決方案的推廣應用，正將診斷監測的範圍從醫院擴展到其他場所，尤其是在高風險產後管理方面。這項轉變涉及使用連網血壓監測儀和遠端醫療平台，從而實現持續的生理監測，確保及時應對可能被忽略的高血壓高峰。事實證明，該策略對於降低與再次入院相關的產婦發病率以及在產後關鍵階段維持護理的連續性至關重要。根據發表在2024年8月《婦產科計畫》（The ObG Project）上的一篇題為「遠距血壓監測計畫對妊娠高血壓患者產後護理的影響」的論文，參與遠距高血壓管理計畫與產後6週內再次入院率的顯著降低相關，與標準照護相比，調整後的風險比為0.78。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：妊娠相關高血壓診斷的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類別（設備、耗材、其他）
    • 依最終使用者（醫院、專科診所、診斷中心等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美妊娠相關高血壓診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲妊娠相關高血壓診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區妊娠相關高血壓診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲妊娠相關高血壓診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲妊娠相關高血壓診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球妊娠相關高血壓診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Diabetomics Inc.
  • DRG INSTRUMENTS GMBH
  • F. Hoffmann-La Roche Ltd
  • Afekta Technologies Ltd.
  • MOMM Diagnostics GmbH
  • PerkinElmer Inc.
  • Sera Prognostics, Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24595

The Global Preeclampsia Diagnostics Market is projected to expand from USD 849.03 Million in 2025 to USD 1109.47 Million by 2031, registering a compound annual growth rate of 4.56%. This sector comprises medical devices and laboratory assays-such as blood pressure monitors, proteinuria testing kits, and placental growth factor biomarkers-developed to identify hypertensive disorders during pregnancy. Growth is largely fueled by the increasing global incidence of maternal risk factors, including obesity, chronic hypertension, and advanced maternal age, which demand strict prenatal monitoring. Additionally, the incorporation of early risk assessment protocols into routine antenatal care and government-led initiatives to lower maternal mortality rates provide foundational support for market expansion, independent of specific technological trends.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 849.03 Million
Market Size 2031USD 1109.47 Million
CAGR 2026-20314.56%
Fastest Growing SegmentConsumables
Largest MarketNorth America

However, market growth faces a substantial obstacle regarding the affordability and accessibility of specific biomarker tests in low-resource regions, where the burden of disease is frequently the heaviest. This inequality restricts the broad implementation of effective screening tools needed to prevent severe clinical outcomes. Data from the Preeclampsia Foundation in 2024 indicates that approximately 76,000 mothers and 500,000 infants die globally each year due to preeclampsia and associated hypertensive disorders, highlighting the critical nature of these diagnostic gaps.

Market Driver

Technological progress in biomarker-based diagnostic assays acts as a pivotal market driver, shifting the standard of care from reactive management toward predictive risk stratification. The industry is rapidly adopting assays that evaluate angiogenic factors, such as the sFlt-1/PlGF ratio, which provide predictive accuracy superior to traditional blood pressure and proteinuria checks. For instance, Labcorp's May 2024 announcement regarding their 'First Trimester Preeclampsia Screening Test' noted that the new method achieved a sensitivity of up to 90% in detecting early-onset risk, significantly outclassing conventional assessments. This level of diagnostic precision promotes broad uptake within clinical workflows to enable prompt interventions, thereby directly boosting revenue for diagnostic manufacturers.

Concurrently, the expanding addressable market is bolstered by the rising incidence of hypertensive disorders during pregnancy. This trend correlates closely with advanced maternal age and the increasing prevalence of chronic conditions, such as obesity and diabetes, among women of reproductive age. According to the March of Dimes '2024 Report Card' released in November 2024, the national rate of pre-pregnancy hypertension rose by over 10% between 2022 and 2023, requiring frequent diagnostic monitoring for an enlarging high-risk demographic. The extensive reach of the condition is highlighted by a May 2024 Femtech Insider article, 'Labcorp Introduces New Screening Test for Preeclampsia Risk,' which states that roughly one in 25 pregnancies in the United States is currently impacted by preeclampsia, underscoring the urgent need for accurate diagnostic solutions.

Market Challenge

The prohibitive cost and limited availability of specialized biomarker tests in low-resource environments represent a primary constraint on the Global Preeclampsia Diagnostics Market. Although the clinical necessity for strict prenatal monitoring is intense in developing regions, financial and infrastructural shortcomings often prevent the acquisition of advanced diagnostic devices and laboratory assays. This disparity precludes market participants from securing a presence in high-volume geographies, effectively confining the total addressable market to primarily high-income nations. As a result, the disconnect between disease prevalence and economic purchasing power retards the global adoption rate of these vital tools.

This economic hurdle directly affects industry revenue by leaving a substantial segment of the global patient population without access to care. The inability to penetrate these markets leads to a considerable loss in potential volume growth, as manufacturers are unable to scale operations in areas where the clinical burden is most severe. According to a 2024 report by the World Health Organization, approximately 92% of all maternal deaths took place in low- and lower-middle-income countries. This statistic illustrates a profound market imbalance, wherein the regions with the greatest implied need for diagnostics possess the least capacity to access them, thereby suppressing overall industry expansion.

Market Trends

The integration of AI-driven predictive analytics is fundamentally transforming the market landscape by facilitating non-invasive, highly accurate screening methods that process complex physiological data. This trend transcends standard protein assays by utilizing machine learning algorithms to examine novel inputs, such as retinal vascular changes, for earlier disease detection. These digital tools enhance the scalability of screening and provide predictive capabilities that exceed traditional risk factor assessments, encouraging the creation of software-as-a-medical-device products. As reported by Medscape in the March 2024 article 'AI Identifies Retinal Biomarkers for Preeclampsia,' a newly evaluated AI framework called DVT-Net achieved an accuracy level of 0.813 for early prediction during the first and second trimesters, significantly improving the identification of at-risk patients prior to symptom onset.

Simultaneously, the expansion of remote and home-based monitoring solutions is extending diagnostic supervision beyond hospital settings, specifically for high-risk postpartum management. This shift entails the use of connected blood pressure devices and telehealth platforms that enable continuous physiological tracking, ensuring timely responses to hypertensive spikes that might otherwise go unnoticed. This strategy is proving essential for lowering maternal morbidity rates linked to hospital readmissions and maintaining care continuity during the critical postpartum phase. According to an August 2024 article by The ObG Project titled 'How Does Remote BP Monitoring Program Impact Postpartum Care for Those with Hypertensive Disorders of Pregnancy?,' participation in a remote hypertension management program was linked to a significantly reduced six-week postpartum readmission rate, demonstrating an adjusted risk ratio of 0.78 compared to standard care.

Key Market Players

  • Diabetomics Inc.
  • DRG INSTRUMENTS GMBH
  • F. Hoffmann-La Roche Ltd
  • Afekta Technologies Ltd.
  • MOMM Diagnostics GmbH
  • PerkinElmer Inc.
  • Sera Prognostics, Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.

Report Scope

In this report, the Global Preeclampsia Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Preeclampsia Diagnostics Market, By Product

  • Instruments
  • Consumables
  • Others

Preeclampsia Diagnostics Market, By End User

  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Others

Preeclampsia Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Preeclampsia Diagnostics Market.

Available Customizations:

Global Preeclampsia Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Preeclampsia Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Instruments, Consumables, Others)
    • 5.2.2. By End User (Hospitals, Specialty Clinics, Diagnostic Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Preeclampsia Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Preeclampsia Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Preeclampsia Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Preeclampsia Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By End User

7. Europe Preeclampsia Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Preeclampsia Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By End User
    • 7.3.2. France Preeclampsia Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Preeclampsia Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Preeclampsia Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Preeclampsia Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By End User

8. Asia Pacific Preeclampsia Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Preeclampsia Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By End User
    • 8.3.2. India Preeclampsia Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Preeclampsia Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Preeclampsia Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Preeclampsia Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By End User

9. Middle East & Africa Preeclampsia Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Preeclampsia Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Preeclampsia Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Preeclampsia Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By End User

10. South America Preeclampsia Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Preeclampsia Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Preeclampsia Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Preeclampsia Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Preeclampsia Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Diabetomics Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. DRG INSTRUMENTS GMBH
  • 15.3. F. Hoffmann-La Roche Ltd
  • 15.4. Afekta Technologies Ltd.
  • 15.5. MOMM Diagnostics GmbH
  • 15.6. PerkinElmer Inc.
  • 15.7. Sera Prognostics, Inc.
  • 15.8. Siemens Healthineers AG
  • 15.9. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer